Halozyme Reports Strong Quarterly Results and Raises Full-Year Outlook - Stock with Up-Gap!

Halozyme is a biopharmaceutical technology company with a unique business model, as it does not develop its own drugs and licenses its technology through its Enhanze platform to biopharmaceutical companies for the co-development of products. I first reported extensively about the company in 2022 in the Tenbagger magazine. On May 6, the company impressed with very strong numbers and a year-over-year revenue growth of 35% to $265 million. A share buyback program of $250 million was announced for the year 2025. Growth was significantly driven by royalties...